Switching from twice‐daily abacavir and lamivudine to the once‐daily fixed‐dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy

Patients prefer fewer pills and once‐daily (qd) dosing without food restrictions. We assessed the impact on adherence [by Medication Event Monitoring System (MEMS) cap monitoring] of switching from abacavir (ABC) and lamivudine (3TC) twice daily (bid) to ABC/3TC fixed‐dose formulation (FDC, Kivexa®) qd to achieve a qd regimen.

[1]  B. Yip,et al.  Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated With Increased Mortality and Poor Adherence to Therapy , 2005, Journal of acquired immune deficiency syndromes.

[2]  J. Phair,et al.  Determinants of Heterogeneous Adherence to HIV‐Antiretroviral Therapies in the Multicenter AIDS Cohort Study , 2001, Journal of acquired immune deficiency syndromes.

[3]  B. Gazzard,et al.  British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2005) , 2005, HIV medicine.

[4]  B. Gazzard,et al.  Better maintained adherence on switching from twice‐daily to once‐daily therapy for HIV: a 24‐week randomized trial of treatment simplification using stavudine prolonged‐release capsules , 2005, HIV medicine.

[5]  D. Back,et al.  The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. , 1999, AIDS.

[6]  G. Moyle.  The Assessing Patients’ Preferred Treatments (APPT-1) study , 2003, International journal of STD & AIDS.

[7]  J. Tolson,et al.  Perspectives on Adherence and Simplicity for HIV-Infected Patients on Antiretroviral Therapy: Self-Report of the Relative Importance of Multiple Attributes of Highly Active Antiretroviral Therapy (HAART) Regimens in Predicting Adherence , 2004, Journal of acquired immune deficiency syndromes.

[8]  D. Nau,et al.  The relationship of disease severity, health beliefs and medication adherence among HIV patients , 2000, AIDS care.

[9]  British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy , 2000 .

[10]  L. Kalish,et al.  Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease , 2001, Annals of Internal Medicine.

[11]  M. Johnson,et al.  A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. , 2007, AIDS research and human retroviruses.

[12]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[13]  C. Leen,et al.  A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy , 2006, AIDS.

[14]  V. Soriano,et al.  Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. , 1999, AIDS.

[15]  M. Avison,et al.  Interscience Conference on Antimicrobial Agents and Chemotherapy , 2001 .

[16]  R. Grant,et al.  Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Cramer,et al.  A systematic review of the associations between dose regimens and medication compliance. , 2001, Clinical therapeutics.

[18]  A. LaMarca,et al.  Efficacy and Safety of a Once-Daily Fixed-Dose Combination of Abacavir/Lamivudine Compared With Abacavir Twice Daily and Lamivudine Once Daily as Separate Entities in Antiretroviral-Experienced HIV-1-Infected Patients (CAL30001 Study) , 2006, Journal of acquired immune deficiency syndromes.

[19]  B. Gazzard,et al.  Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation , 2008, Antiviral therapy.

[20]  P. Cahn,et al.  Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults: Results of the Ziagen Once Daily in Antiretroviral Combination Study , 2005, Journal of acquired immune deficiency syndromes.

[21]  C. Cohen,et al.  Pilot Study of a Novel Short-Cycle Antiretroviral Treatment Interruption Strategy: 48-Week Results of the Five-Days-On, Two-Days-Off (FOTO) Study , 2007, HIV clinical trials.

[22]  J. Caylà,et al.  Impact of Adherence and Highly Active Antiretroviral Therapy on Survival in HIV‐Infected Patients , 2002, Journal of acquired immune deficiency syndromes.

[23]  R. Hays,et al.  A Comparison Study of Multiple Measures of Adherence to HIV Protease Inhibitors , 2001, Annals of Internal Medicine.

[24]  A. Wu,et al.  Self‐Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection , 2001, Journal of acquired immune deficiency syndromes.

[25]  Carol E Golin,et al.  Knowledge of antiretroviral regimen dosing and adherence: a longitudinal study. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Shuter,et al.  HIV-Infected Patients Receiving Lopinavir/Ritonavir-Based Antiretroviral Therapy Achieve High Rates of Virologic Suppression Despite Adherence Rates Less Than 95% , 2007, Journal of acquired immune deficiency syndromes.

[27]  G. Wagner,et al.  Electronic monitoring: Adherence assessment or intervention? , 2002, HIV clinical trials.